This document discusses pharmacovigilance and the role of consumers in reporting adverse drug reactions (ADRs) in India. It outlines how India established a pharmacovigilance program to monitor ADRs. Underreporting of ADRs by healthcare professionals is a limitation, so consumer reporting can help detect more ADRs earlier, especially for over-the-counter drugs. India has launched forms and a mobile app to facilitate consumer ADR reporting to strengthen pharmacovigilance. While consumer reporting cannot replace healthcare professional reporting, it can complement it.